Cargando…

NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis

The molecular mechanism underlying non‐alcoholic fatty liver disease progression to hepatocellular carcinoma (HCC) remains unknown. In this study, immunohistochemistry staining results showed that NS5ABP37 protein, which is in a state of lower expression in tumor tissues, decreased with increasing d...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Shenghu, Han, Ming, Zhou, Li, Wang, Qi, Li, Zhongshu, Li, Yaru, Lu, Hongping, Liu, Ting, Ma, Yanhua, Liu, Shunai, Cheng, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5276832/
https://www.ncbi.nlm.nih.gov/pubmed/27862769
http://dx.doi.org/10.1111/cas.13117
_version_ 1782502349142491136
author Feng, Shenghu
Han, Ming
Zhou, Li
Wang, Qi
Li, Zhongshu
Li, Yaru
Lu, Hongping
Liu, Ting
Ma, Yanhua
Liu, Shunai
Cheng, Jun
author_facet Feng, Shenghu
Han, Ming
Zhou, Li
Wang, Qi
Li, Zhongshu
Li, Yaru
Lu, Hongping
Liu, Ting
Ma, Yanhua
Liu, Shunai
Cheng, Jun
author_sort Feng, Shenghu
collection PubMed
description The molecular mechanism underlying non‐alcoholic fatty liver disease progression to hepatocellular carcinoma (HCC) remains unknown. In this study, immunohistochemistry staining results showed that NS5ABP37 protein, which is in a state of lower expression in tumor tissues, decreased with increasing degree of HCC malignancy. Two cell models, HepG2 and L02, were used to analyze the mechanism between NS5ABP37 and HCC. In agreement, NS5ABP37 protein overexpression significantly suppressed cell proliferation, caused G(1)/S cell cycle arrest, and induced apoptosis by increasing caspase‐3/7 activity and cleaved caspase‐3 levels. In addition, NS5ABP37 overexpression resulted in decreased intracellular triglyceride and total cholesterol contents, with level reduction in sterol regulatory element‐binding proteins (SREBPs) and downstream effectors. Furthermore, NS5ABP37 overexpression decreased SREBP1c and SREBP2 levels by reducing their respective promoters. Finally, reactive oxygen species levels and endoplasmic reticulum stress were both induced by NS5ABP37 overexpression. These findings together indicate that NS5ABP37 inhibits cancer cell proliferation and promotes apoptosis, by altering SREBP‐dependent lipogenesis and cholesterogenesis in HepG2 and L02 cells and inducing oxidative stress and endoplasmic reticulum stress.
format Online
Article
Text
id pubmed-5276832
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-52768322017-02-01 NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis Feng, Shenghu Han, Ming Zhou, Li Wang, Qi Li, Zhongshu Li, Yaru Lu, Hongping Liu, Ting Ma, Yanhua Liu, Shunai Cheng, Jun Cancer Sci Original Articles The molecular mechanism underlying non‐alcoholic fatty liver disease progression to hepatocellular carcinoma (HCC) remains unknown. In this study, immunohistochemistry staining results showed that NS5ABP37 protein, which is in a state of lower expression in tumor tissues, decreased with increasing degree of HCC malignancy. Two cell models, HepG2 and L02, were used to analyze the mechanism between NS5ABP37 and HCC. In agreement, NS5ABP37 protein overexpression significantly suppressed cell proliferation, caused G(1)/S cell cycle arrest, and induced apoptosis by increasing caspase‐3/7 activity and cleaved caspase‐3 levels. In addition, NS5ABP37 overexpression resulted in decreased intracellular triglyceride and total cholesterol contents, with level reduction in sterol regulatory element‐binding proteins (SREBPs) and downstream effectors. Furthermore, NS5ABP37 overexpression decreased SREBP1c and SREBP2 levels by reducing their respective promoters. Finally, reactive oxygen species levels and endoplasmic reticulum stress were both induced by NS5ABP37 overexpression. These findings together indicate that NS5ABP37 inhibits cancer cell proliferation and promotes apoptosis, by altering SREBP‐dependent lipogenesis and cholesterogenesis in HepG2 and L02 cells and inducing oxidative stress and endoplasmic reticulum stress. John Wiley and Sons Inc. 2017-01-29 2017-01 /pmc/articles/PMC5276832/ /pubmed/27862769 http://dx.doi.org/10.1111/cas.13117 Text en © 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Feng, Shenghu
Han, Ming
Zhou, Li
Wang, Qi
Li, Zhongshu
Li, Yaru
Lu, Hongping
Liu, Ting
Ma, Yanhua
Liu, Shunai
Cheng, Jun
NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis
title NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis
title_full NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis
title_fullStr NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis
title_full_unstemmed NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis
title_short NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis
title_sort ns5abp37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5276832/
https://www.ncbi.nlm.nih.gov/pubmed/27862769
http://dx.doi.org/10.1111/cas.13117
work_keys_str_mv AT fengshenghu ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis
AT hanming ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis
AT zhouli ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis
AT wangqi ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis
AT lizhongshu ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis
AT liyaru ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis
AT luhongping ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis
AT liuting ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis
AT mayanhua ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis
AT liushunai ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis
AT chengjun ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis